https://www.selleckchem.com/pr....oducts/belvarafenib.
g., osteopenia/osteoporosis. We observed that close to 80% of the patients presenting such manifestations had the genotype AA. However, we did not find any significant involvement of the FOXO3 polymorphism in clinical manifestation occurrences. Thus, we concluded that the SNP rs3800231 did not play a significant role as a modifier of the clinical manifestations observed in the β-thal homozygotes studied. Thus, we concluded that the SNP rs3800231 did not play a significant role as a modifier of the clinical manifestations observed i
Like
Comment
Share
